The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
DNA repair
biomarkers
homologous recombination deficiency
loss of heterozygosity
poly (ADP-ribose) polymerase (PARP) inhibitors
precision oncology
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
received:
11
08
2023
revised:
05
09
2023
accepted:
07
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The
Identifiants
pubmed: 37761329
pii: diagnostics13182962
doi: 10.3390/diagnostics13182962
pmc: PMC10529941
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Onco Targets Ther. 2022 Feb 24;15:165-180
pubmed: 35237050
Nat Commun. 2021 May 3;12(1):2487
pubmed: 33941784
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
JCO Precis Oncol. 2022 Jun;6:e2100531
pubmed: 35772050
JCO Precis Oncol. 2017 Nov;1:1-13
pubmed: 35172494
Clin Cancer Res. 2022 Apr 1;28(7):1412-1421
pubmed: 34740923
Bioinformatics. 2021 Jul 27;37(13):1909-1911
pubmed: 32449758
Breast Cancer Res Treat. 2019 Apr;174(3):627-637
pubmed: 30607631
Cancer Res Treat. 2020 Oct;52(4):1135-1144
pubmed: 32340084
Front Oncol. 2020 Apr 28;10:570
pubmed: 32457830
Nat Commun. 2020 Nov 4;11(1):5584
pubmed: 33149131
NPJ Breast Cancer. 2019 Aug 8;5:23
pubmed: 31428676
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
J Transl Med. 2021 Sep 8;19(1):385
pubmed: 34496866
Cancer Discov. 2021 Nov;11(11):2812-2827
pubmed: 34045297
J Genet Couns. 2018 Feb;27(1):131-139
pubmed: 28780754
Cancers (Basel). 2022 Jun 15;14(12):
pubmed: 35740616
Per Med. 2014 Mar;11(2):197-210
pubmed: 29751382
Oncologist. 2022 Mar 11;27(3):167-174
pubmed: 35274707
Biomark Res. 2019 Nov 15;7:25
pubmed: 31807308
Transl Oncol. 2020 Feb;13(2):410-422
pubmed: 31901781
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
ESMO Open. 2021 Jun;6(3):100144
pubmed: 34015643
Cancers (Basel). 2021 Feb 24;13(5):
pubmed: 33668244
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Mod Pathol. 2021 Jun;34(6):1185-1193
pubmed: 33462368
Int J Mol Sci. 2017 Jan 04;18(1):
pubmed: 28054957
Cancers (Basel). 2022 Aug 27;14(17):
pubmed: 36077694
Recent Pat Anticancer Drug Discov. 2018;13(4):392-410
pubmed: 29512470
Nature. 2022 Oct;610(7931):343-348
pubmed: 36071165